HC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN - Get Free Report)'s stock had its "neutral" rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.

Agenus Stock Performance

NASDAQ AGEN opened at $3.83 on Wednesday. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69. The company has a fifty day moving average of $3.12 and a 200-day moving average of $5.04. The company has a market capitalization of $89.85 million, a P/E ratio of -0.34 and a beta of 1.27.

Hedge Funds Weigh In On Agenus

A number of large investors have recently modified their holdings of AGEN. FMR LLC increased its holdings in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company's stock worth $467,000 after buying an additional 27,309 shares during the period. HighTower Advisors LLC grew its position in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 37,866 shares during the period. Geode Capital Management LLC grew its holdings in shares of Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company's stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company's stock worth $2,563,000 after buying an additional 9,731 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.